Home Search

citius - search results

If you're not happy with the results, please do another search
cITIUS

Citius (CTXR) Announces Results of Mino-Lok Study.

"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Issam Radd

Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

2021 and 2020 Milestones In Plain Sight. Locked and Loaded for most of 2020 - many major milestone...

Citius Pharma (CTXR) Video Presentation.

Chairman Leonard Mazur Discusses: Mino-Lok Treatment for Infected Catheters. Novellus Stem Cell Treatment...
citius pharma, biotech stock review

Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!

Great headline, right? The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million

Where is Citius Pharma (CTXR) in the FDA Approval Process?

We have a number of subscribers asking for an update on the FDA approval process for Mino-Lok. In layman's term (assuming approval)...

Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.

VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
Citius Pharma

Citius Pharma (CTXR) On The Move.

One Of Our Top 5 Biotech Picks For 2020 Up 23% Yesterday, Indicating Up Another 24% This Morning. Inquiring Minds Want...

Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...

Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).   Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
Biotech Stock Review, Novellus, Citius

Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.

Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure.

Latest article

ENDRA, Biotech Stock Review

Heads UP: ENDRA Life Science (NDRA) $1.50, up 40% Today.

Are Expectations of a 501K Approval Perking Up? We've learned through trial and error (with the better...
Internet Stock Review

Is the Bitcoin Bubble More Fraud Than Frenzy?

Research Affiliates Quant Warns of Bitcoin Market Manipulation (Bloomberg) (Bloomberg) -- In 2017, Alex Pickard had made so...

Make Hay While the Sun Shines. Up 6,400%.

Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have...